Provectus Pharmaceuticals Inc. Receives Patent in India for Lead Oncology Product

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB:PVCT) (http://www.pvct.com) has received a patent in India protecting its lead oncology agent, PV-10, along with a number of related agents. The patent covers injectable and other forms of the drugs, including capsules, tablets, and oral suspensions and solutions. A range of active compounds are protected, each related to the active ingredient in PV-10.

Back to news